Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the Companyâs core areas of neurology, orphan and specialty medicines. Assertio currently markets three FDA-approved products and continues to identify, license and develop new products that offer enhanced options for patients that may be underserved by existing therapies. Source
No articles found.
Allakos is a clinical-stage company developing therapeutic antibodies that selecti...
Allakos is a clinical-stage company developing ...
Tonix is a clinical-stage biopharmaceutical company focused on discovering and dev...
Tonix is a clinical-stage biopharmaceutical com...
Sophiris Bio Inc. is a late-stage biopharmaceutical company developing topsalysin ...
Sophiris Bio Inc. is a late-stage biopharmaceut...
Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, ...
Galapagos develops therapies with proprietary, ...
The Medicines Company is a biopharmaceutical company driven by an overriding purpo...
The Medicines Company is a biopharmaceutical co...
Savara is an orphan lung disease company. Savaraâs pipeline comprises Molgradex,...
Savara is an orphan lung disease company. Savar...
Anavex utilizes precision genetic medicine to treat severe and devastating neurolo...
Anavex utilizes precision genetic medicine to t...
Join the National Investor Network and get the latest information with your interests in mind.